GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

NCT04779697 · Completed

Last updated 2026-05-28

This clinical trial tests whether a GLP-1 analogue affects food cravings, stress, motivation for high-calorie foods, and weight in adults with obesity.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind study

Participants 96 people

Who can join Ages 18–55 · all sexes

Timeline Started 2021-02 · est. completion 2024-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04779697 ↗

Description as written by the study sponsor.

To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.

Treatments tested

GLP-1 analogue - semaglutide also known as Semaglutide Drug

GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks
Placebo Other

Placebo - administered once weekly for a total of 12 weeks

Main thing measured	Change in Craving Score
Sponsor	Yale University
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04779697 ↗